Dalgety and Grow Pharma sign distribution agreement
The English medical cannabis producer, Dalgety, recently announced the signing of a new distribution agreement with Grow Pharma. This collaboration will enable the marketing in the UK market of prescription medicines rich in THC and pharmaceutical grade. The first product resulting from this collaboration is expected by the end of 2023, marking a major breakthrough in the UK’s medical cannabis sector.
One step closer to legalizing cannabis for medical use in the UK
Patients still waiting for suitable solutions
Despite the legalization of cannabis for medical use in the UK in 2018, many patients suffering from chronic pain or conditions such as epilepsy are still unable to access cannabis-based treatments. Indeed, current legislation makes it difficult for general practitioners to prescribe these medications. With this new partnership between Dalgety and Grow Pharma, it should now be possible to offer solutions adapted to British patients.
A cultivation license obtained in early 2023
Thanks to obtaining a medical cannabis cultivation license obtained at the start of the year, Dalgety will now be able to produce pharmaceutical grade cannabis on British territory. Ultimately, the first cannabis medicine grown in the UK will be accessible to patients and controlled by local health authorities.
A promising collaboration between Dalgety and Grow Pharma
This partnership between Dalgety and Grow Pharma promises to be fruitful, in particular thanks to their complementarity. On the one hand, Dalgety benefits from recognized expertise in the production of medical cannabis. On the other hand, Grow Pharma specializes in the importation and distribution of medicinal cannabis-based medicines.
The joint project between these two companies aims to facilitate access to cannabis-based medicines for patients who need them on the British market while ensuring optimal pharmaceutical quality.
The benefits of medical cannabis
- Fight against chronic pain: certain components of cannabis can significantly reduce inflammation and relieve pain.
- Seizure control: Cannabidiol (CBD) has been shown to be an effective treatment for reducing epileptic seizures in children with Dravet syndrome.
- Reduction of chemotherapy-related side effects: Cannabis may offer some support in managing nausea and loss of appetite caused by cancer treatments.
It is essential to emphasize that the use of cannabis for medical purposes must always be supervised and supervised by a health professional.
A promising start to a new era of medical cannabis in the UK
The anticipated arrival of the first cannabis-based medicinal product grown on British soil marks a significant milestone in the development of the UK’s medical cannabis market. Indeed, this progress could open the door to new legislation more favorable to the use of cannabis for medical purposes.
While many patients are still suffering today due to a lack of suitable solutions, the collaboration between Dalgety and Grow Pharma seems to bring hope for all those who are impatiently waiting for the end of 2023.
